Ads targeting a selected patient class may lack fair balance if class-specific risks/dosage are not adequately emphasized

AI-verifiedwarningBinding lawRaised as a question — a person decides

Rule

An advertisement promoting use of the drug in a selected class of patients (for example, geriatric or depressed patients) may be false, lacking in fair balance, or otherwise misleading if it fails to present with adequate emphasis the significant side effects and contraindications, or — when dosage recommendations are included in the advertisement — the significant dosage considerations, especially applicable to that selected class of patients.

Check

Identify whether the piece promotes use in a selected patient class; if so, assess whether the significant class-relevant side effects and contraindications receive adequate, non-buried emphasis, and — only if the advertisement includes dosage recommendations — whether the significant class-relevant dosage considerations do as well.

Escalate when

Whether the emphasis given to class-specific side effects, contraindications, or (where applicable) dosage considerations is 'adequate' turns on layout, prominence, and overall impression — escalate to a human reviewer whenever it is unclear if the de-emphasis or omission rises to the level of a fair-balance violation for that selected class.

Where this comes from

21 CFR 202.1(e)(7)(x). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

… typography, layout, contrast, headlines, paragraphing, white space, and any other techniques apt to achieve emphasis. (ix) Fails to provide adequate emphasis (for example, by the use of color scheme, borders, headlines, or copy that extends across the gutter) for the fact that two facing pages are part of the same advertisement when one page contains information relating to side effects and contraindications. (x) In an advertisement promoting use of the drug in a selected class of patients (for example, geriatric patients or depressed patients), fails to present with adequate emphasis the significant side effects and contraindications or the significant dosage considerations, when dosage recommendations are included in an advertisement, especially applicable to that selected class of patients. (xi) Fails to present on a page facing another page (or on another full page) of an advertisement on more than one page, information relating to side effects and contraindications when such information is in a distinct part of the advertisement. (xii) Fails to include on each page or spread of an advertisement the information relating to side effects and contraindications or a prominent reference to its presence a…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Mediumprintbroadcast

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Quote is verbatim from 21 CFR 202.1(e)(7)(x) and the locator is correct; the parenthetical examples (geriatric, depressed patients) used in the rule statement come from the same clause, so the rule's subject matter is genuinely established by the source.
- Overstated: the clause falls under the (e)(7) chapeau, 'Advertisements that may be false, lacking in fair balance, or otherwise misleading. An advertisement may be false ... if it:'. That is a 'may be misleading if' factor, deliberately distinguished in the same source text from the (e)(6) 'Advertisements that are false...' list. The rule renders it as a flat obligation ('must adequately emphasize'), which is stronger than the source.
- Overstated: the source conditions the dosage limb on 'when dosage recommendations are included in an advertisement' and uses 'or' between the risk limb and the dosage limb. The rule uses 'and' and drops the conditional, so it would demand class-specific dosage emphasis in ads containing no dosage recommendations.
- Overstated: the source qualifies both limbs with 'significant' ('the significant side effects and contraindications or the significant dosage considerations'); the rule drops that qualifier and reads as covering all side effects and contraindications.
- applies_when is under-specified: it carries only 'promotional' and omits two limits present in the source: (a) Section 202.1 governs prescription-drug advertisements (see (l)(1) enumerating journal, magazine, newspaper, radio, television and telephone advertisements), and (b) the clause is triggered only by 'an advertisement promoting use of the drug in a selected class of patients'. As encoded, the rule would fire on every promotional piece.
- Determinism 'judgment' is correct: 'adequate emphasis' is an impression/prominence test that no presence-absence or literal match can settle.
- Authority 'binding' is correct: 21 CFR 202.1 is a codified regulation, and non-compliant advertisements are deemed to misbrand the drug under section 502(n) per paragraph (k).
- Severity 'warning' is defensible and consistent with the permissive 'may be' framing of the (e)(7) list.
- Atomicity is acceptable: the risk limb and dosage limb share one trigger (class-specific promotion) and one test (adequate emphasis), so they need not be split, provided the dosage limb is conditioned as the source conditions it.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is the full text of (e)(7)(x) and appears in the operative list, not in a definition, example, or preamble. The locator 21 CFR 202.1(e)(7)(x) matches the position of the quoted clause in the source (it sits between (ix) on facing-page emphasis and (xi) on distinct-part placement).
- Not overstated: the rule statement reproduces the governing chapeau of paragraph (e)(7) verbatim in force — 'An advertisement may be false, lacking in fair balance, or otherwise misleading' — rather than converting the permissive 'may be' into a flat prohibition. The 'when dosage recommendations are included' condition from the source is preserved as a condition in both the rule and the check, not dropped.
- Atomic: the source frames this as one violation condition triggered by a single predicate (promotion in a selected patient class), with two alternative manifestations joined by 'or' within one clause. The check keeps the dosage limb explicitly conditional, so a reviewer evaluates a single failure mode rather than two unrelated obligations.
- Determinism correctly set to 'judgment': liability turns on 'adequate emphasis,' which the neighboring provisions ((e)(7)(viii)) expressly tie to typography, layout, contrast, headlines, white space and other emphasis techniques. No literal presence/absence test resolves it. The escalate-when language is consistent with this.
- Authority correctly 'binding': 21 CFR 202.1 is a codified regulation, and non-compliant advertisements are deemed to misbrand the drug under section 502(n) per paragraph (k) of the same source.
- applies_when is defensible on this source: (e)(7)(x) speaks only of 'an advertisement,' and paragraph (l)(1) of the same section scopes advertisements subject to 502(n) to published journals/magazines/periodicals/newspapers and broadcast media, while (l)(2) classifies brochures, detailing pieces, mailers and similar items as labeling rather than advertising. Limiting to print and broadcast therefore tracks the source rather than inventing a limit. Note for downstream use: (l)(1) uses 'include,' so the list is non-exhaustive and a future revision may reasonably extend the medium list; that is not a defect against this excerpt.
- Severity 'warning' is defensible: the paragraph is cast as conduct that 'may be' violative rather than a per se prohibition, and the finding depends on a judgment about emphasis, so a warning with human escalation is proportionate.